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Background: Injecting risk behaviour, such as receptive sharing of injecting equipment and/or re-
using one’s equipment, is associated with bloodborne virus transmission and infections in people 
who inject drugs (PWID). We aimed to estimate prevalence and correlates of injecting risk 
behaviours among PWID. 
Methods: We conducted a systematic review and meta-analyses to estimate country, regional, 
and global prevalences of injecting risk behaviours (including sharing or re-using needle/syringe 
and sharing other injecting equipment). Using meta-regression analyses, we determined 
associations between study- and country-level characteristics and receptive needle/syringe 
sharing.  
Results: From 61,077 identified papers and reports and 61 studies from expert consutation, 
evidence on injecting risk behaviours was available for 464 studies from 88 countries. Globally, it 
is estimated that 17.9% (95%CI: 16.2-19.6%) of PWID engaged in receptive needle/syringe 
sharing at last injection, 23.9% (95%CI: 21.2-26.5%) in the past month, and 32.8% (95%CI: 28.6-
37.0%) in the past 6-12 months. Receptive sharing of other injecting equipment was common. 
Higher prevalence of receptive needle/syringe sharing in the previous month was associated with 
samples of PWID with a lower proportion of females, shorter average injecting duration, a higher 
proportion with >daily injecting, and older studies. Countries with lower development index, 
higher gender inequality and lower NSP coverage had higher proportions reporting receptive 
needle/syringe sharing.   
Conclusions: High levels of injecting risk behaviours were observed among PWID globally, 
although estimates were only available for half of the countries with evidence of injecting drug 
use. There is a need for better capture of injecting risk behaviours in these countries to inform 









A 2017 systematic review found evidence of injecting drug use (IDU) in 179 countries containing 
99% of the world population, with between 10.2-23.7 million people who inject drugs (PWID) 
globally1. There are a range of injecting practices which may carry varying levels of risk to an 
individual and be amenable to differing interventions to reduce such risk. These include (but are 
not limited to) sharing needles/syringes; reusing one’s own needle/syringe for multiple 
injections; and sharing or reusing other injecting equipment, such as filters and spoons for 
dissolving drugs for injection2. Sharing injecting equipment causes substantial disease burden, 
primarily due to transmission of blood-borne viruses (BBV), including human immunodeficiency 
virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV). Globally, estimates suggest that 
approximately one in six people who have recently injected drugs are living with HIV1, two in five 
are currently infected with HCV3, and one in 10 have active HBV1. Through unsafe injecting 
techniques, particularly using non-sterile equipment, PWID are also at increased risk of exposure 
to bacterial infections4. 
Sharing injecting equipment and other injecting risk behaviours can arise through no or limited 
access to sterile needles, syringes and injecting equipment5. Poor injecting technique and 
injecting risk behaviour can also develop in response to marginalisation, which can be created by 
criminal sanctions of drug use6. Marginalisation and stigma can act to reduce awareness and/or 
use of existing harm reduction services, which may reduce opportunities for accessing sterile 




risk environments (e.g. police confrontations, incarceration, unstable housing)1,9 that are 
associated with increased likelihood of unsafe injecting behaviours (e.g. public injecting, 
needle/syringe sharing, not using swabs to clean the injection site), thereby placing them at 
greater risk of drug-related harm10-13.  
A range of factors may be associated with the likelihood of injecting risk behaviours. These may 
include individual characteristics such as gender, age, duration of injecting career and the types 
of drugs being injected, which may affect frequency of injecting14-17. They may also include 
exposure to riskier environments such as living in unstable housing. As well as individual factors, 
structural and community-level factors may be contributing to variation. These might include 
drug market characteristics and drug policy that govern the availability of different drug types; 
as well as governmental and social responses to injecting drug use and people who inject drugs, 
including availability of interventions known to reduce injecting risk (needle and syringe 
programmes, opoid agonist treatment (OAT))18,19. Depending on the country and region, the 
number of PWID and coverage of program interventions targeting harms associated with 
injecting risk behaviours can differ quite substantially1,20. Broader societal characteristics such as 
income inequality, gender equality and country-level development may affect attitudes towards 
and marginalisation of PWID. However, the relationship between these country-level factors and 
injecting risk behaviours has, to our knowledge,  not previously been explored since most studies 
are conducted in a single country, precluding study of variation between countries.  
To our knowledge, there has not previously been a global systematic review of the extent of 
injecting risk behaviours among PWID at a country, regional, and global level. Such information 




related harms, and ensure such policies are targeted at those at greater risk, and to both highlight 
and respond to more systemic barriers to harm reduction. As such, we aimed to: 
1. Estimate the proportion of PWID engaging in injecting risk behaviours at country, regional, 
and global levels;  
2. Explore variation in the estimated prevalence of receptive needle/syringe sharing with 
estimated country-level NSP and OAT coverage; and 
3. Explore associations between injecting risk behaviours and study-level factors (e.g., 
sociodemographic, drug use and other behavioural characteristics of PWID samples) and 








We conducted a global systematic review in accordance with GATHER and PRISMA guidelines 
(Appendix 1). This review is based on data from a systematic literature search focusing on the 
prevalence of IDU and characteristics of PWID, details of which are described elsewhere1. Briefly, 
we conducted systematic searches in July 2016 through peer-reviewed databases (Medline, 
Embase, and PsycINFO) for papers and reports published from 2008 onwards. Search terms 
included exploded MeSH terms and keywords for IDU and epidemiology (Appendix 2). We did 
not limit our search by language. We also searched the key websites and grey literature (see 
Appendix 3). The peer-reviewed database searches were updated to July 2018. Data requests 
were also disseminated to international experts and agencies. The protocols are registered on 
PROSPERO (CRD42016052858 and CRD42016052853).  
Screening and extraction 
Title/abstract and full-text screening was conducted by two authors, and disputes were resolved 
by a third author. Included studies were collated into an EndNote database and extracted into a 
custom Microsoft Access Database by one team-member and double-checked by a second, 
senior team-member. We excluded studies that did not include data on PWID specifically, were 
randomised-controlled trials, investigated a sub-population (e.g. people living with HIV), or had 




We extracted injecting risk variables for five timeframes: last injection, past month, past 6 
months, past 12 months, and lifetime. The pre-specified injecting risk variables extracted are 
listed in Table 1.  
Table 1 about here 
For each eligible study, we extracted data on pre-defined socio-demographic characteristics, drug 
use and other behavioural data. Study-level variables included year of data collection, sample 
size, method of recruitment (e.g. NSP centres, peer referrals, and surveys), sex, age (median, 
mean, and/or range), length of time injecting (in years), frequency of injecting (extracted by the 
categories defined in the original study and then grouped as daily or more and less than daily 
injecting; for more detail see21), incarceration history (past 12 months and lifetime), 
homelessness or unstable housing (within the past year), current engagement in opioid agonist 
therapy (OAT), and opioids as main drug injected.  
Country-level variables included study region (Eastern Europe, Western Europe, Australasia, 
Pacific Island States and Territories, South Asia, East and South East Asia, Central Asia, Middle 
East and North Africa, Sub-Saharan Africa, North America, Caribbean, and Latin America; see 
Appendix for a list of countries in each region), Human Development Index score, Gender 
Inequality Index score, income inequality as measured by the Gini coefficient22. 
Associations between injecting risk behaviour and OAT and NSP coverage, operationalised as the 
number of needles/syringes distributed per 100 PWID5 and the number of people receiving OAT 




earlier multistage systematic review5, also conducted in accordance with GATHER and PRISMA 
guidelines. That review was also registered on PROSPERO (CRD42017056558); full details of the 
methods used are described elsewhere5. 
Data analysis 
Estimates for each injecting risk behaviour were pooled by country using random-effects meta-
analysis in Stata 15.0 (StataCorp, College Station, TX, USA). For the purposes of capturing the 
most recent evidence for each variable, the most recent 5 years of estimates were used for each 
country (e.g. we included estimates from 2011-2015 for a given country if the most recent 
estimate for receptive needle/syringe sharing in the past month was from 2015). Country-level 
estimates were then pooled using the same method to generate a regional estimate, and then 
an overall global estimate. 
Using estimates of the number of needle-syringes distributed per PWID per year5 and the number 
of people receiving OAT per 100 PWID per year5, we generated scatterplots to examine potential 
associations between country-level NSP coverage and OAT coverage, and the estimated country-
level pooled proportion of PWID reporting receptive needle/syringe sharing in the past 6-12 
months.  
Where we had data available, we examined the association between the prevalence of injecting 
risk behaviours and study- and country-level characteristics. Using meta-regression analysis, we 
undertook bivariate analyses of associations of injecting risk behaviour with study- and country-
level variables. We excluded variables from this analysis that were available for fewer than 25% 






The search found a total of 61,077 reports/papers and 61 reports provided via expert 
consultation, of which 464 eligible papers/reports contained data on injecting risk behaviours 
among PWID (for study flowchart, see Appendix 4). The full list of identified eligible studies is 
reported in Appendix 5. 
Overall, studies of injecting risk behaviours among PWID were identified for 88 out of 179 
countries with evidence of injecting drug use (49%; Table 2). The most commonly studied 
behaviours were receptive needle/syringe sharing, receptive injecting equipment sharing, and 
needle/syringe re-use (Appendix 6). The most commonly reported timeframes were at last 
injection and past month, with 6 months and 12 months being combined for the analyses below. 
Most studies were conducted in single cities (54%) or other sub-national (37%) settings with 
recruitment occurring between 1996 and 2016 (see Appendix 6).  
Estimates of receptive needle/syringe sharing were identified for the largest number of countries 
(n=36 countries for last injection, n=42 for past month, and n=31 for past 6-12 months; Table 2). 
Data on re-use of one’s own needle/syringe, and on receptive sharing of other injecting 
equipment, were scarcer (Table 2) and typically reported for the past month.  
To summarise country-level data, we present pooled estimates of the proportion of PWID 
reporting receptive needle/syringe sharing, receptive sharing of other equipment, and 




using the most recent five years of data identified for each country are reported below (pooled 
estimates using all available data can be found in Appendix 7; results were similar). Estimates of 
the proportion of PWID who reported engaging in other injecting risk behaviours, including 
distributive needle/syringe sharing, being injected by someone else, and not cleaning injecting 
site before injecting (e.g. by swabbing), were less commonly located. Studies reporting these can 
be found in Appendix 8 and 9.  
Table 2 about here 
Receptive needle-syringe sharing 
Data on receptive needle/syringe sharing was the most widely collected injecting behaviour 
among PWID (Table 2). Eastern Europe had the largest number of countries (and greatest 
proportion of countries) with data on this behaviour. Globally, it is estimated that 17.9% (95% 
confidence interval [95%CI]: 16.2-19.6%) of PWID engaged in receptive needle/syringe sharing at 
last injection, 23.9% (95%CI: 21.2-26.5%) in the past month, and 32.8% (95%CI: 28.6-37.0%) in 
the past 6-12 months (Table 3). Regional estimates are displayed for past month receptive 
needle/syringe sharing in Figure 1a  and country estimates in Figure 1b (see Appendix 10 for 
maps of regional and country estimates for past 6-12 months receptive needle/syringe sharing). 
Figure 1 about here 
There was variation between countries and regions in levels of receptive needle/syringe sharing. 
Middle East and North Africa (33.5%, 95%CI: 5.4-61.7%, 3/21 countries with evidence of IDU), 
South Asia (32.1%, 95%CI: 26.0-38.3%, 5/9 countries with evidence of IDU) and Eastern Europe 




estimates of receptive needle/syringe sharing in the last month. Within Eastern Europe, 
estimates ranged greatly from 8.5% (95%CI: 8.0-9.0%) in Ukraine to 80.6% (95%CI: 71.3-90.0%) 
in Azerbaijan. The lowest pooled estimates of receptive needle/syringe sharing in the last month 
were for Western Europe and Australasia (Australia) at 9.8% (95%CI: 7.1-12.5, 6/33 countries 
with evidence of IDU) and 10.6% (95%CI: 7.5-13.6), respectively.  
Receptive sharing of other injecting equipment 
Seventeen countries had studies reporting on receptive sharing of other injecting equipment 
(Table 2) across any reporting period, with country-level estimates shown in Table 3. Receptive 
sharing of other injecting equipment was common at last injection (20.1%, 95%CI: 12.2-28.0%), 
within the past month (30.5%, 95%CI: 21.2-39.8%), and past 6-12 months (36.2%, 95%CI: 29.6-
42.9%) (Table 3). Limited data coverage across countries limited capacity to make firm 
conclusions about any geographical differences. 
Re-using one’s own needle-syringe 
Out of the 36 countries where data of reusing one’s own needles and syringes were available, 
the majority (17 countries) assessed this behaviour within the past month. Reusing one’s own 
needle/syringe was reported by 49.1% (95%CI: 40.1-58.1%) of PWID within the past month. Data 
were much sparser for other timeframes (Table 2). Limited data coverage across countries 
limited capacity to make firm conclusions about any geographical differences. 




Examining variation in estimated prevalence of receptive needle/syringe sharing with 
estimated country-level NSP and OAT coverage 
There were 25 countries with available data for NSP coverage and past 6-12 months receptive 
needle/syringe sharing (Figure 2a; 81% of countries with estimates of past 6-12 months receptive 
needle/syringe sharing and 14% of countries with evidence of any IDU). Notably, all countries 
(n=5) with a pooled estimate of >50% prevalence of receptive needle/syringe sharing in the past 
6-12 months also had low or no NSP coverage (<50 needles distributed per PWID per year). 
Countries with lower injecting risk estimates appeared to have higher estimates of NSP coverage. 
This was less distinct when examining the relationship between NSP coverage and receptive 
needle and syringe sharing within the past month (see Appendix 11).  
Figure 2b illustrates the countries with available OAT coverage data and receptive needle/syringe 
sharing in the past 6-12 months (n=27 countries; 87% of countries with estimates of past 6-12 
months receptive needle/syringe sharing and 14% of countries with evidence of injecting drug 
use). Past month data are shown in Appendix 12.  
Figure 2 about here 
Associations of injecting risk behaviours with study- and country-level variables 
Given available data, we only undertook meta-regressions examining associations between 
study- and country-level variables with receptive needle/syringe sharing in the past month. 
Meta-regressions using study-level variables of incarceration history and current engagement in 
OAT were not conducted as <25% of the studies with an estimate of receptive needle/syringe 




receptive needle/syringe sharing in the past month was associated with several factors (Table 4). 
At the study-level, these include a shorter average injecting duration of the sample, a higher 
proportion of PWID reporting injecting daily or more, a lower proportion of PWID who are 
female, and older studies. Upon examining country-level factors, studies conducted in Western 
European, Australasian, and East and South East Asian samples had lower proportions of PWID 
reporting past-month receptive needle/syringe sharing compared to Eastern European samples. 
Furthermore, countries with lower development and higher gender inequality, as indicated by 
lower Human Development Index (HDI) and higher Gender Inequality Index (GII) scores, had 
higher proportions of PWID samples reporting receptive needle/syringe sharing.  Higher country-
level NSP coverage was associated with a lower reported engagement with receptive 
needle/syringe sharing in the past month (Table 4). No association was found between country-
level OAT coverage and proportion of PWID reporting receptive needle/syringe sharing in the 
past month (Table 4). 






In this global systematic review, it is estimated that 23.9% (95%CI: 21.2-26.5%) of PWID had 
engaged in receptive needle/syringe sharing in the past month. Similarly, high proportions of 
PWID reported sharing other injecting equipment (30.5%, 95%CI: 21.2-39.8%) and resuse of one’s 
own needle/syringe (49.1%, 95%CI: 40.1-58.1%) in the past month. A higher proportion of PWID 
reporting receptive needle/syringe sharing in the previous month was associated with samples 
of PWID with a higher proportion that were female, a shorter average injecting duration, a higher 
proportion with >daily injecting, and older studies. Countries with lower development index and 
higher gender inequality had higher proportions of receptive needle/syringe sharing. Ecological 
associations between lower NSP coverage and increased injecting risk behaviours were observed, 
and all countries reporting >50% of PWID shared needles/syringes recently had no NSP 
programmes at all.  
Data on injecting risk behaviours were only available for 49% of countries with evidence of 
injecting. Our review of sociodemographic characteristics of PWID from which these data are 
drawn1 identified many more studies than included here, highlighting the lack of systematic 
capture and reporting on injecting risk behaviours. Given targets for global HIV and HCV 
elimination23-25  it is important that these behaviours are closely monitored into the future to 
better understand harm reduction service needs among PWID and opportunities for educate 
regarding injecting practices.  Variation in the types of injecting risk behaviours assessed and in 
how those injecting risk behaviours were defined, coupled with a lack of detail regarding the 




reinforce the need for standardisation of definitions of injecting risk behaviours across studies, 
to increase the consistency and relaibility of estimates of injecting risk behaviours across settings.  
Where injecting risk behaviour has been assessed, it is clear that a large percentage of PWID do 
engage in risk, which can lead to the perseverance of ongoing BBV epidemics that cause huge 
disease burden26. The highest pooled estimates of receptive needle/syringe sharing in the last 
month were found in the Middle East and North Africa, South Asia, and Eastern Europe, with 
approximately one third of PWID reporting this injecting risk behaviour in the past month. 
Western Europe and Australasia (Australia) had the lowest pooled prevalence, with 
approximately one in 10 PWID estimated to receptively share needles/syringes in the past 
month. Notably, those countries with no or lower NSP coverage typically had higher pooled 
estimates of receptive needle/syringe sharing, and NSP coverage was inversely associated with 
the proportion of PWID reporting past month receptive needle-syringe sharing. 
This review also highlighted that PWID living in countries with lower human development had 
higher levels of injecting risk, suggesting that indicators of a country’s outcomes related to life 
expectancy, education and gross national income27 are related to risk. The higher proportion of 
past month receptive needle and syringe sharing could be a reflection of lower scoring countries 
having reduced resources to spend on educational and harm reducation interventions including 
NSP provision and OAT. 
The finding that greater gender inequality, measured through  the disparity between men and 
women in the domains of healthcare, employment, education and government, was related to 




more dependent on their sexual partners and experience greater injecting-related stigma, 
leading to increase receptive needle and syringe sharing and lower engagement with harm 
reduction services when compared to men28-31. This may also lead to barriers to accessing harm 
reduction services and sterile injecting equipment29,30.  
These findings reinforce that widespread availability and provision of clean needles, syringes and 
other injecting equipment for PWID is crucial to reduce re-use of needles and syringes. Educating 
PWID about the risks of unsafe injecting and ways to make injecting less risky is important and 
there are effective interventions to address this, which are also inexpensive to deliver32-34. There 
is good evidence that OAT reduces the extent of injecting risk behaviour among people who are 
opioid dependent35,36. Finally, increasing the capacity of PWID to inject in a safe environment 
without fear of detection, harassment or police interactions is important; in areas where there is 
considerable public (and perhaps risky) injection, supervised injecting sites provide a clean, safe 
and secure environment for people to inject37,38. 
It is also important to consider sociodemographic characteristics of those with elevated risk of 
injecting risk behaviour to inform targeted intervention. Meta-regression analyses of age did not 
show an association with the proportion of PWID reporting past-month receptive needle/syringe 
sharing. By contrast, shorter duration of injecting was associated with a greater proportion of 
PWID reporting past-month receptive needle/syringe sharing. Other studies also have shown 
that HIV and HCV incidence are higher in the first years of injecting39,40. Intervening early to 
ensure recent PWID are linked to harm reduction services and educated regarding safer injecting 





Our review was subject to limitations (discussed in detail previously1). First, despite our relatively 
wide scope of online searches and requests for information from people across many countries, 
grey literature reports can be difficult to access. Undoubtedly, we have missed some of these 
studies. To address this as much as possible, we liaised directly with international agencies to 
facilitate contact with people in-country and obtain reports that were not available online.  
Second, many documents were reviewed by a small research team in a short period of time, so 
we may have missed some information in this process. However, internal checks were conducted 
and a process of double and triple checking was used. Further, the estimates produced were 
circulated to all potential authors for input, allowing for identification of missing or incorrect 
data.  
The results presented were limited by the availability of injecting risk behaviour data. The lack of 
studies resulted in some regional estimates being based on one or two studies, especially for re-
using one’s own needles/syringes and receptive sharing of other equipment. There were 
instances where there were very wide confidence intervals around country and regional 
estimates, and in some cases inconsistencies in estimates across timeframes. For example, a 
single study in China had very low 6-12 month prevalence of receptive injecting risk, compared 
to higher estimated past month injecting risk derived from multiple studies. These kinds of 
inconsistencies must be taken into account when considering the robustness of the data. 
The main method to collect information on injecting risk among the studies was to administer a 




injecting risk behaviour may underestimate the level of risk in the population – through a 
combination of response biases relating both to memory and willingness to report negative 
behaviours, though responses are fairly reliable and valid41. Many of the studies also recruited 
participants through NSPs or advertisements; the PWID captured through these studies may 
represent those who are also engaged in harm reduction or treatment services. This could mean 
that the pooled estimates presented in this study may be an underestimate of the actual 
prevalence of injecting risk behaviours among broader populations of PWID who are not in 
contact with harm reduction or treatment services.  
Conclusion 
Existing studies of injecting risk behaviour among PWID have often revealed high levels of a range 
of injecting risk behaviour, likely contributing to the high burden of infections and BBVs among 
this population. This calls for public health interventions to support safe injecting behaviours in 
this population. Despite the importance of this risk for the health of PWID, assessments are 
inconsistent in their definitions and timeframes, and for many countries we did not locate any 
studies documenting how common these behaviours might be. Such data are crucial to inform 
service planning, consider the extent of need for key harm reduction interventions, and evaluate 
potential impacts of interventions to reduce risk. These data are critical to inform future planning 
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Table 1: Summary of injecting risk behaviours extracted 
Behaviour Definition 
Receptive needle and syringe sharing Using a needle or syringe after someone else has already used it 
Distributive needle and syringe sharing Allowing someone else to use a needle or syringe after you have used it 
Unspecified needle and syringe sharing Type of needle or syringe sharing was not clearly defined 
Receptive sharing of other equipment Using other injecting equipment (e.g., cotton, filter, spoon, tourniquet) after someone else has used it 
Distributive sharing of other equipment Allowing someone else to use other injecting equipment after you have used it 
Unspecified sharing of other equipment Type of other injecting equipment sharing was not clearly defined 
Receptive sharing of any equipment Using any injecting equipment after someone else has already used it 
Distributive sharing of any equipment Allowing someone else to use any injecting equipment after you have used it 
Unspecified sharing of any equipment Type of any injecting equipment sharing was not clearly defined 
Re-using any of your own equipment Using any of your injecting equipment more than once 
Re-using your own needles and syringes Using any of your needles or syringes more than once 
Re-using your own other equipment Using any of injecting equipment, except needle and syringes, more than once 
Injected by someone else Having someone else inject you instead of doing it yourself 
No filter used Not using a filter to remove impurities before injecting 
No sterile needle and syringe A sterile needle or syringe was not used to inject (where it was not clear whether the question referred 
to use by another person prior, re-use by the same individual or other situation in which a 
needle/syringe could be considered non-sterile) 
No cleaning of injecting site The site of injection was not cleaned before injecting (e.g., swabbing) 












No. countries with data on receptive 
sharing of needles 
No. countries with data on re-use own 
needle 
No. countries with data on receptive 
sharing of other equipment 
   at last 
injection 
in the past 
month 





in the past 
month 





in the past 
month 
in the past 
6-12 
months 
Eastern Europe 17 17 7 13 5 1 5 - 1 3 - 
Western Europe 33 31 3 6 3 - 2 1 1 3 1 
East and Southeast Asia 17 16 6 5 4 2 1 - - 1 - 
South Asia 9 9 5 5 5 3 3 2 1 2 1 
Central Asia 5 5 3 - 3 - - 1 - - - 
Caribbean 15 6 - 1 - - - - - - - 
Latin America 20 19 3 - 2 - - - - - 1 
North America 2 2 - 2 2 - 1 1 - 1 2 
Pacific Island states & 
territories1 
17 15 - - - - - - - - - 
Australasia 2 2 - 1 2 - 1 - - 1 - 
Sub-Saharan Africa 47 36 5 6 5 - 3 - 1 - - 
Middle East & North 
Africa 
22 21 4 3 - - 1 1 1 - - 






Table 3: Country-level estimates of injecting risk behaviours reported among people who inject drugs (PWID) at last injection, in the past month 
and in the past 12 months 
 Receptive needle/syringe sharing Re-using own needle and syringe Sharing other equipment 
 At last injection In the past month In the past 6-12 
months 
At last injection In the past month In the past 6-12 
months 
At last injection In the past month In the past 6-12 
months 
Australasia -- 10.6 (7.5-13.6) 30.4 (27.7-33.2) -- 38.1 (30.3-45.8) -- -- 49.4 (43.2-55.7) -- 
Australia -- 10.6 (7.5-13.6) 26.4 (22.1-31.2) -- 38.1 (30.3-45.8) -- -- 49.4 (43.2-55.7) -- 
New Zealand -- -- 32.9 (29.4-36.4) -- -- -- -- -- -- 
Caribbean  13.4 (8.8-19.3) -- -- -- -- -- -- -- 
Puerto Rico  13.4 (8.8-19.3) -- -- -- -- -- -- -- 
Central Asia 17.8 (11.1-24.4) -- 42.0 (16.9-67.1) -- -- 51.9 (47.3-56.6) -- -- -- 
Kazakhstan 20.7 (17.2-24.5) -- 54.1 (49.6-58.5) -- --  -- -- -- 
Kyrgyzstan 11.7 (10.0-13.4) -- 18.5 (15.2-22.1) -- --  -- -- -- 
Tajikistan 24.6 (20.6-28.9) -- 53.6 (48.8-58.4) -- -- 51.9 (47.3-56.6) -- -- -- 
East and South East Asia 25.5 (17.4-33.6) 17.0 (11.3-22.7) 35.4 (17.5-53.3) 4.7 (2.9-6.5) 33.0 (24.2-42.8) -- -- 22.4 (6.9-37.9) -- 
Cambodia 35.3 (28.1-43.0) 33.5 (26.5-41.2) -- 31.9 (23.7-41.1) 33.0 (24.2-42.8) -- -- -- -- 
China 14.4 (13.6-15.3) 29.8 (20.4-39.1) 9.9 (7.6-12.3) -- -- -- -- 22.4 (6.9-37.9) -- 
Indonesia 4.1 (3.5-4.8) 10.3 (5.8-14.7) -- -- -- -- -- -- -- 
Malaysia -- 47.9 (43.3-52.6) -- -- -- -- -- -- -- 
Myanmar 18.9 (14.4-23.3) -- 32.3 (25.1-40.2) 3.6 (2.1-5.0) -- -- -- -- -- 
Philippines 56.6 (25.3-88.0) -- 72.2 (55.6-88.8) -- -- -- -- -- -- 
Thailand 7.4 (4.2-12.0) -- -- -- -- -- -- -- -- 
Viet Nam -- 9.6 (5.8-13.5) 12.3 (0.0-26.3) -- -- -- -- -- -- 
Eastern Europe 10.3 (8.2-12.3) 31.1 (24.5-37.7) 24.7 (15.0-34.4) 29.1 (24.6-33.9) 49.6 (38.0-61.2) -- 5.5 (3.0-7.9) 53.5 (35.5-71.5) -- 
Armenia 21.0 (16.7-25.2) 12.1 (5.2-18.9) -- -- -- -- -- -- -- 
Azerbaijan 42.8 (14.1-71.6) 80.6 (71.3-90.0) -- -- -- -- -- -- -- 
Belarus 9.7 (5.8-13.6) 12.0 (7.0-17.0) -- -- 45.4 (35.8-54.9) -- -- -- -- 
Bosnia & Herzegovina 8.2 (6.5-9.9) 29.5 (2.8-56.1) 18.4 (14.3-22.5) -- -- -- -- -- -- 
Bulgaria -- 40.0 (37.8-42.2) 40.0 (36.7-43.4) -- 25.1 (22.2-28.2) -- -- -- -- 
Czech Republic -- -- 29.6 (25.5-34.0) -- -- -- -- -- -- 
Estonia -- 23.5 (19.1-28.3) 14.4 (10.6-18.9) -- -- -- -- -- -- 
Georgia 5.9 (3.3-8.4) 19.1 (13.9-24.4) -- -- -- -- 5.5 (3.0-7.9) 48.0 (35.3-60.7) -- 
Latvia -- 35.2 (29.7-41.1) -- -- -- -- -- -- -- 
Lithuania -- 67.2 (61.6-72.5) -- -- -- -- -- -- -- 
Moldova (Republic of) -- 10.1 (2.6-17.7) -- -- -- -- -- -- -- 
Romania 17.6 (15.0-20.2) 31.6 (28.8-34.4) -- 29.1 (24.6-33.9) 74.7 (71.6-77.8) -- -- -- -- 
Russian Federation -- 24.9 (17.2-32.6) 25.2 (18.6-32.6) -- 74.0 (69.8-78.2) -- -- 84.7 (82.7-86.5) -- 
Ukraine 3.3 (2.6-4.1) 8.5 (8.0-9.0)  -- 35.0 (34.0-36.0) -- -- 48.1 (47.1-49.1) -- 
Latin America 25.0 (14.4-35.5) -- 52.7 (29.6-75.7) -- -- -- -- -- 54.2 (50.1-58.3) 
Colombia 14.7 (11.7-17.6) -- 42.0 (37.9-46.1) -- -- -- -- -- 54.2 (50.1-58.3) 
Mexico 28.7 (25.6-32.0) -- 71.4 (68.0-74.7) -- -- -- -- --  
Nicaragua 46.3 (30.7-62.6) -- -- -- -- -- -- -- -- 
Middle East and North 
Africa 




 Receptive needle/syringe sharing Re-using own needle and syringe Sharing other equipment 
 At last injection In the past month In the past 6-12 
months 
At last injection In the past month In the past 6-12 
months 
At last injection In the past month In the past 6-12 
months 
Israel 11.1 (7.1-16.3) 19.1 (13.9-25.3) -- -- -- -- -- -- -- 
Morocco 23.8 (12.0-35.5)  -- -- 81.1 (77.8-84.4) 54.7 (47.8-61.5) -- -- -- 
Occupied Palestinian 
Territory 
10.9 (6.9-16.2) 19.1 (13.9-25.3) -- -- -- -- 31.3 (24.8-38.3) -- -- 
Syrian Arab Republic 19.5 (15.7-23.8) 62.5 (56.6-68.0) -- -- -- -- -- -- -- 
North America -- 21.5 (3.8-39.3) 27.7 (23.7-31.7) -- 37.1 (33.4-40.7) 20.8 (14.5-28.4)  17.3 (13.2-22.1) 41.3 (34.5-48.1) 
Canada -- 20.4 (17.6-23.3) 15.8 (13.7-17.9) --  20.8 (14.5-28.4)   38.0 (34.8-41.2) 
United States of America -- 22.7 (0.0-46.1) 34.4 (30.0-38.7) -- 37.1 (33.4-40.7)   17.3 (13.2-22.1) 57.0 (56.1-57.9) 
South Asia 20.1 (17.2-22.9) 32.1 (26.0-38.3) 26.0 (14.6-37.5) 22.6 (13.2-32.0) 55.6 (28.7-82.6) 38.3 (29.7-46.9) 33.8 (12.9-54.7) 10.4 (4.2-16.6) 12.2 (8.7-16.4) 
Afghanistan -- -- 6.9 (1.9-11.8) -- -- -- -- -- -- 
Bangladesh 50.3 (23.5-77.0) 54.8 (43.5-66.1) -- -- -- -- -- -- -- 
India 13.5 (11.4-15.6) 22.0 (13.4-30.6) 33.7 (32.1-35.3) 24.5 (13.9-35.1)  36.9 (28.2-45.6) 33.8 (12.9-54.7) -- -- 
Iran (Islamic Republic of) -- 20.4 (1.1-39.7) 47.4 (44.8-50.1) -- 43.4 (39.0-47.9) 59.8 (55.4-64.1) -- 54.1 (40.8-66.9) -- 
Maldives 23.4 (18.5-28.4) -- -- -- -- -- -- -- -- 
Nepal 0.9 (0.2-1.6) 16.9 (6.1-27.6) 51.0 (45.2-56.8) 1.0 (0.3-1.7) 4.6 (3.1-6.1) -- -- 3.5 (0.3-6.6) 12.2 (8.7-16.4) 
Pakistan 23.7 (17.6-29.8) 42.1 (36.8-47.4) 17.2 (16.0-18.4) -- 74.7 (63.8-85.6) -- -- -- -- 
Sri Lanka -- -- -- 57.5 (50.6-64.3) -- -- -- -- -- 
Sub-Saharan Africa 34.9 (20.4-49.4) 23.0 (16.1-30.0) 40.5 (27.7-53.4)  49.5 (31.7-67.3) -- 34.1 (32.2-35.9) -- -- 
Benin -- 25.0 (17.5-33.7) -- -- -- -- -- -- -- 
Côte d'Ivoire -- 1.8 (0.0-9.4) -- -- -- -- -- -- -- 
Kenya 6.4 (5.3-7.5) 44.1 (39.3-48.8) -- -- 56.0 (47.7-64.1) -- 34.1 (32.2-35.9) -- -- 
Madagascar -- -- 19.3 (8.1-30.4) -- -- -- -- -- -- 
Mauritius 10.8 (8.2-13.9) -- 42.4 (38.0-46.9) -- -- -- -- -- -- 
Nigeria -- 17.7 (8.4-27.0) -- -- 33.1 (27.1-39.4) -- -- -- -- 
Senegal -- -- -- -- 60.0 (51.4-68.2) -- -- -- -- 
Seychelles 21.7 (16.6-27.6) 30.9 (26.1-36.1) -- -- -- -- -- -- -- 
Sierra Leone 74.6 (68.2-80.4) -- 60.0 (53.8-66.0) -- -- -- -- -- -- 
South Africa 48.9 (44.3-53.5) -- 46.2 (35.9-56.5) -- -- -- -- -- -- 
Tanzania (United 
Republic of) 
-- 31.2 (28.2-34.1) 67.1 (55.6-77.3) -- -- -- -- -- -- 
Western Europe 11.7 (4.5-18.9) 9.8 (7.1-12.5) 43.3 (33.1-53.5) -- 45.4 (42.4-48.5) 65.1 (60.5-69.5) 14.6 (0.0-29.6) 24.2 (16.2-32.2) 28.0 (25.3-30.7) 
Albania 25.5 (19.6-32.1) 39.5 (32.7-46.6) -- -- -- -- -- -- -- 
Belgium -- 20.8 (17.1-24.5) -- -- 45.2 (38.5-52.1) -- -- 18.7 (13.8-24.4) -- 
Croatia 3.9 (0.0-8.3) 14.1 (0.0-28.5) -- -- -- -- 14.6 (0.0-29.6) -- -- 
Germany -- -- -- -- 45.5 (42.0-49.1) -- -- -- -- 
Montenegro -- 26.0 (20.9-31.6) -- -- -- -- -- -- -- 
Serbia 16.8 (13.5-20.0) 5.2 (3.3-7.1) -- -- -- -- -- 3.7 (2.2-5.3) -- 
Spain -- -- 45.1 (43.3-46.8) -- -- 65.1 (60.5-69.5) -- -- -- 
Sweden -- -- 43.1 (39.4-46.8) -- -- -- -- -- -- 
United Kingdom -- 2.5 (1.3-3.7) 43.9 (31.6-56.2) -- -- -- -- 27.4 (24.7-30.1) 28.0 (25.3-30.7) 
   Scotland -- 2.5 (1.3-3.7) 46.7 (42.6-50.9) -- -- -- -- 27.4 (24.7-30.1) 28.0 (25.3-30.7) 




Note: Please see Appendix 6 pp.90-94 for details of data sources in this table, and for a complete list of the countries in each region, including countries where 




Figure 1: Regional (top) and country (bottom) pooled estimates of the percentage of people 






Table 4: Association of study- and country-level variables with past month receptive 
needle/syringe sharing among people who inject drugs (PWID) 




Coefficient SE 95% CIs p 
Study-level variables      
Percentage of sample that are female 178 -0.20 0.08 (-0.37, -0.03) 0.019 
Median/mean age of sample (years) 183 0.00 0.00 (-0.01, 0.00) 0.242 
Mean injecting duration of the sample (years) 130 -0.01 0.00 (-0.02, 0.00) 0.005 
Year of data collection 201 -0.02 0.00 (-0.03, -0.01) <0.001 
Percentage of sample injecting daily or more 124 0.27 0.06 (0.16, 0.39) <0.001 
Percentage of sample recently homeless/with unstable housing 73 0.18 0.14 (-0.09, 0.45) 0.192 
Percentage of sample whose main drug injected was opioids 48 0.15 0.11 (0.07, 0.36) 0.183 
Country-level variables      
Region           
 Eastern Europe (ref.) 58         
    Western Europe  21 -0.19 0.05 (-0.29, -0.09) <0.001 
    Australasia 24 -0.16 0.05 (-0.26, -0.07) 0.001 
    The Americas 17 -0.06 0.05 (-0.17, 0.05) 0.284 
    East and South east Asia 19 -0.13 0.05 (-0.24, -0.03) 0.013 
    South Asia 44 0.08 0.04 (0.00, 0.16) 0.053 
    Middle East and Africa 18 -0.05 0.05 (-0.16, 0.06) 0.361 
Human Development Index 2016 201 -0.46 0.11 (-0.67, -0.25) <0.001 
Gender Inequality Index 2014 191 0.40 0.09 (0.22, 0.59) <0.001 
Income inequality (Gini coefficient) 199 -0.41 0.31 (-1.02, 0.21) 0.191 
NSP coverage (number of needles/syringes per PWID per year) 184 -0.45E-3 0.10 (-0.64E-3, -0.25E-3) <0.001 
OAT coverage (number of people in OAT per 100 PWID) 190 -0.38E-3 0.22 (-0.82E-3, 0.07E-3) 0.093 




Figure 2: Estimated percentage of people who inject drugs (PWID) engaging in receptive needle/syringe 
sharing in the previous 6-12 months, compared to the estimated number of needles-syringes distributed per 
PWID per year (top) and number of OAT clients per 100 PWID (bottom)
 
 
Note the estimates of needles-syringes distributed per PWID per year and number of OAT clients per 100 PWID per year were taken from earlier 
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